Weighted average price of α-GPC, ₩512

Ginkgo leaf dried ext., ₩110

The HIRA releases data every year for use, such as preparing economic evaluation data

The weighted average price of Choline alfoscerate 0.4g, which was the subject of reevaluation of the adequacy of benefits last year, decreased 0.2% from the previous year to ₩512.

 

The weighted average price of Vitis vinifera 50mg.

 

and Avocado-Soya unsaponifiables 0.3g, which are undergoing re-evaluation this year, decreased by 1.7% and 5.3%, respectively, compared to the previous year.

 

Dailypharm recently revealed this trend as a result of calculating the low-dose weighted average price of major ingredients over the last three years based on the '2020 yearly weighted average price of drug per year' that the HIRA recently released.

 

The data released this time was calculated as a weighted average price of 3, 554 ingredients for health insurance review in the previous year for items listed on the drug benefit list as of February 1 of this year.

 

The weighted average price of each major ingredient was reduced by 2.9% for Donepezil 10mg, a dementia treatment drug, from ₩1,971 in 2019 to ₩1,941 in 2020.

 

The weighted average price of Amlopidine besylate 5 mg, a hypertension drug, was calculated last year at ₩358 (-0.3%), and the average price of the combination drug Amlodipine besylate 10 mg/ Telmisartan 80 mg was calculated at ₩845 (-0.7%), and The average price of Amlodipine besylate/Valsartan 80mg was calculated as ₩982 (no change).

 

The price of Ezetemib 10mg/Rosuvastatin 5mg, a combination treatment for hyperlipidemia, was cut last year to ₩883 (-0.3%), and the price of Clopidogrel was reduced to ₩1,118 (-0.9%).

 

The weighted average price of Ginkgo leaf dried extract 0.12g last year was ₩110, the weighted average price of Bilberry dried extract 0.17g was ₩238, and the weighted average price of Silymarin 0.35g was ₩401, the same as the previous year.

 

The weighted average price by active ingredient is used as a reference price when preparing drug economic evaluation data or negotiating drug prices.

 

The weighted average price released this time was excluded from calculation when there was no billing performance last year, when the upper limit price could not be calculated or Amino acid preparation.

 

The same ingredient, same formulation, and same dosage were calculated by weighted average value with the same main ingredient.

 

The formulation code was TB·CH·CS as TB, CE·TE as TE, CR·TR as TR, and GN·PD is calculated as GN, CM·OM·PA as OM, PC·PL·PO as PL, and SY·SS as SY.

 

In the case of product code changes due to transfer, the amount of claim for the item before the change is incorporated into the item after the change.

 

For patent-related items, the upper limit of the item is calculated as a weighted average price.